Sorbitol plus chemo and immunotherapy for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with stomach or gastroesophageal junction cancer that is HER2-negative and has not been treated yet.
- Your cancer is locally advanced (stage cT3-4N+M0) and is a type called adenocarcinoma.
- You are in good physical condition (ECOG score 0 or 1).
- Your major organs (blood, liver, kidneys) are working well based on blood tests.
- You are not pregnant and agree to use birth control during and for 8 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy after surgical removal of stomach cancer can prevent the cancer from returning in older adults (aged 65 and above). The study aims to see if this combination improves outcomes compared to chemotherapy alone.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests whether adding a short course of radiation to a combination of chemotherapy and an immunotherapy drug (called a PD-1 inhibitor) before surgery helps shrink tumors and improve outcomes for people with upper stomach or gastroesophageal junction cancer.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.